News Feature | Published:

Driving T-cell immunotherapy to solid tumors

Nature Biotechnology volume 36, pages 215219 (2018) | Download Citation

Subjects

T cell receptor (TCR) gene therapy can target the immune system to solid tumors in ways CAR-T cells can't match, but the field is still looking for a clear success. Ken Garber reports.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature 308, 145–149 (1984).

  2. 2.

    , , & Nature 308, 149–153 (1984).

  3. 3.

    et al. Nature 320, 232–238 (1986).

  4. 4.

    et al. Science 314, 126–129 (2006).

  5. 5.

    et al. Proc. Natl. Acad. Sci. USA 97, 5387–5392 (2000).

  6. 6.

    et al. J. Clin. Oncol. 29, 917–924 (2011).

  7. 7.

    et al. Mol. Ther. 19, 620–626 (2011).

  8. 8.

    et al. J. Immunother. 36, 133–151 (2013).

  9. 9.

    et al. Blood 122, 863–871 (2013).

  10. 10.

    et al. Blood 122, 348–356 (2013).

  11. 11.

    et al. J. Clin. Oncol. 35, suppl; abstr. 3000 (2017).

  12. 12.

    et al. Clin. Cancer Res. 20, 3401–3410 (2014).

  13. 13.

    et al. Science 344, 641–645 (2014).

  14. 14.

    et al. Mol. Ther. 24, 1078–1089 (2016).

  15. 15.

    et al. Blood 130, 2410–2419 (2017).

  16. 16.

    , , Jr. & J. Clin. Invest. 126, 2404–2411 (2016).

  17. 17.

    et al. Cell 164, 770–779 (2016).

Download references

Author information

Affiliations

  1. Ann Arbor, Michigan

    • Ken Garber

Authors

  1. Search for Ken Garber in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4090